3692 — Hansoh Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapHigh Flyer

Annual income statement for Hansoh Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,690	9,935	9,382	10,104	12,261
Cost of Revenue
Gross Profit	7,887	9,065	8,512	9,071	11,155
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,592	6,582	6,376	6,271	7,169
Operating Profit	3,098	3,353	3,007	3,833	5,092
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	3,098	3,300	2,948	3,766	5,085
Provision for Income Taxes
Net Income After Taxes	2,569	2,713	2,584	3,278	4,372
Net Income Before Extraordinary Items
Net Income	2,569	2,713	2,584	3,278	4,372
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	2,569	2,654	2,584	3,278	4,372
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.437	0.442	0.434	0.543	0.739
Dividends per Share